17.60
+4.51%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Neogenomics
From its filings with the US Securities and Exchange Commission
Neogenomics is based in Fort Myers, Florida and is incorporated in Nevada. Its shares trade on Nasdaq under the ticker NEO. The SEC classifies its business as testing laboratories. In the fiscal year to 31 December 2025, it reported revenue of $727.3m and a net loss of $108.0m. At that date it held total assets of $1.36bn and shareholders' equity of $836.6m.
NeoGenomics provides a wide range of oncology diagnostic testing and consultative services including technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts who specialize in pathology and oncology. We operate a network of cancer-focused testing laboratories in the United States and the United Kingdom. Our mission is to save lives by improving patient care. Our vision is to become the world’s leader in cancer testing, information, and decision support by providing uncompromising quality, exceptional service, and innovative solutions.
We operate under a single segment that encompasses a comprehensive range of services. This approach aims to streamline our operations and enhance our service offerings to our diverse client base, which includes community-based pathology and oncology practices, hospital pathology labs, reference labs, academic centers, and pharmaceutical companies.
Our clinical cancer testing services are designed to complement the work of community-based pathologists and oncologists, allowing them to expand their testing capabilities without significant investment in new technology or personnel. We offer both technical component (“TC” or “tech-only”) and professional component (“PC”) services, enabling our clients to participate in the diagnostic process. These services are designed to be a natural extension of, and complementary to, the services that clients perform within their own practices.
Quoted from its 10-K, filed 17 Feb 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Life Sciences Tools & Services
- Listed since
- 10 Dec 2012
- Employees
- 2,500
- Website
- neogenomics.com ↗
- Head office
- 9490 NEOGENOMICS WAY, FORT MYERS, FL, 33912
- Incorporated in
- NV
- Classification
- Services-Testing Laboratories
- Filer status
- Large accelerated filer
Leadership
Pay as last reported
- Ms. Lynn TetraultIndependent Chairman of the Board, since 2015$218,900
- Mr. Warren StonePresident, Chief Operating Officer$3.2m
- Mr. Antony ZookChief Executive Officer, Director, since 2023$169,157
- Mr. Jeffrey ShermanChief Financial Officer$3.5m
- Ms. Alicia OlivoExecutive Vice President, General Counsel & Business Development$2.2m
- Mr. Gregory AunanChief Accounting Officer
- Mr. Michael KellyLead Independent Director$167,725
- Ms. Marjorie GreenIndependent Director
- Dr. Neil GunnIndependent Director$163,664
- Dr. Alison HannahIndependent Director$158,182
- Mr. Stephen KanovskyIndependent Director$160,850
- Mr. David PerezIndependent Director$159,682
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 65
- Environment
- 71
- Social
- 55
- Governance
- 68
- Direct emissions (scope 1)
- 536 t
- Energy emissions (scope 2)
- 4,181 t
- Women in the workforce
- 59.9%
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Neogenomics Inc holds a prominent position in the molecular testing and genetic analysis market. Its advanced technologies and expertise in oncology diagnostics give it a competitive advantage.
- The company offers a wide range of testing services, including genetic testing, cytogenetics, flow cytometry, and pathology consultations. This diverse portfolio allows Neogenomics to cater to various customer needs.
- Neogenomics has established collaborations with pharmaceutical companies, research institutions, and healthcare providers. These partnerships enhance its research capabilities and provide access to a larger customer base.
Weaknesses
- The company operates in a highly regulated industry where changes in compliance requirements can impact its operations. Ensuring adherence to evolving regulations can be a potential weakness.
- Neogenomics relies on reimbursement from insurance providers and government programs for its testing services. Any changes in reimbursement policies may affect the company's financial performance.
- Maintaining advanced testing technologies and the need for highly skilled professionals contribute to Neogenomics' higher operating costs compared to some competitors.
Opportunities
- The growing focus on personalized medicine creates opportunities for Neogenomics to expand its genetic testing services. Precision medicine can enhance treatment outcomes and drive demand for the company's advanced diagnostics.
- The emergence of liquid biopsy as a non-invasive method for cancer detection presents an opportunity for Neogenomics. Investing in this technology can help the company capture a significant share of the liquid biopsy market.
- Neogenomics can explore new markets beyond the United States to broaden its customer base. International expansion can provide access to untapped revenue streams and diversify its geographical risk.
Threats
- The molecular testing and genetic analysis market is highly competitive, with several established players. Neogenomics faces the risk of losing market share to competitors that offer similar or more innovative services.
- Rapid advancements in technology can quickly make existing diagnostic techniques obsolete. Neogenomics needs to stay at the forefront of technological developments to remain competitive and meet evolving customer expectations.
- During periods of economic recession or downturns in healthcare spending, Neogenomics may experience a decline in demand for its high-cost testing services. The company needs to be prepared for potential fluctuations in market demand.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.